Cariprazine in Three Acute Patients with Schizophrenia: A Real-World Experience

Jose M Montes,1 Paloma Montes,2 Daniel Hernández-Huerta3 1Psychiatry Service, CIBERSAM, IRYCIS, Hospital Universitario Ramóny Cajal, Madrid, Spain; 2Psychiatry Service, Hospital Universitario de Móstoles Madrid, Spain; 3Psychiatry Service, Hospital Universitario Ram&...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Montes JM, Montes P, Hernández-Huerta D
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2021
Materias:
Acceso en línea:https://doaj.org/article/67129604ad4b4012a2dbf1770babe8cd
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Jose M Montes,1 Paloma Montes,2 Daniel Hernández-Huerta3 1Psychiatry Service, CIBERSAM, IRYCIS, Hospital Universitario Ramóny Cajal, Madrid, Spain; 2Psychiatry Service, Hospital Universitario de Móstoles Madrid, Spain; 3Psychiatry Service, Hospital Universitario Ramón y Cajal, Madrid, SpainCorrespondence: Jose M MontesPsychiatry Service, Hospital Universitario Ramón y Cajal, Carretera Colmenar Km 9,1, Madrid, 28034, SpainTel +34 91 336 9152Fax +34 91 336 8483Email j_m_montes@hotmail.comAbstract: There are still some unmet needs in the treatment of schizophrenia like the persistence of negative symptoms. Cariprazine is a new-generation antipsychotic with partial agonism of the dopamine receptors, distinct from other antipsychotics by its 10 times greater affinity for D3 receptors. This mechanism of action could be especially favorable on patients with predominant negative symptoms. This report is showing three clinical cases of acute schizophrenia exacerbation that required hospitalization and were successfully treated with cariprazine. All of them had predominant positive symptoms and two of them had substance use. Efficacy of cariprazine was also crucial on negative and cognitive symptoms with excellent tolerability.Keywords: schizophrenia, cariprazine, antipsychotics, negative symptoms, case report